Peptide Cycle Planning Protocol

Peptide cycling — alternating periods of administration (on-cycle) with periods of cessation (off-cycle) — serves several pharmacological purposes. First, it mitigates receptor desensitization (tachyphylaxis), where continuous agonist exposure downregulates receptor expression or signaling efficacy. Second, it allows assessment of sustained effects versus acute effects. Third, for peptides that modulate endogenous hormone production (e.g., growth hormone secretagogues), cycling prevents suppression of the body's own production via negative feedback.

Categorize each peptide in your protocol: (A) Cycling recommended — GH secretagogues (Ipamorelin, Sermorelin, CJC-1295, GHRP-2/6, Hexarelin, Tesamorelin), melanocortin agonists (PT-141, Melanotan II), pineal peptides (Epithalon). (B) Course-based — Thymalin (5-10 day courses), Epithalon (10-20 day courses). (C) Continuous OK — BPC-157, TB-500 (used for defined healing protocols), GHK-Cu, KPV, metabolic peptides (AOD-9604, MOTS-c, 5-Amino-1MQ). (D) As-needed — DSIP (sleep), PT-141 (specific use).

For cycling peptides, typical on-cycle durations from the literature: GH secretagogues — 8-12 weeks on, then 4-6 weeks off (or 5 days on / 2 days off within a cycle). Melanocortin agonists — use as-needed with minimum 48-72 hours between doses. Epithalon — 10-20 day course, then 4-6 months off. The appropriate on-cycle duration depends on the half-life, receptor pharmacology, and published research for each specific compound.

Washout periods should be long enough for receptor resensitization and clearance of the compound and its downstream effects. General guidelines: short half-life peptides (<1 hour) — minimum 2-4 week washout. Medium half-life peptides (hours to 1 day) — 4-6 week washout. Long half-life peptides (days) — 6-8 week washout. These are conservative estimates; receptor recovery time varies by receptor family.

When using multiple peptides, decide whether to run them concurrently (same time frame) or sequentially (staggered). Concurrent use is appropriate when peptides have complementary mechanisms (e.g., BPC-157 + TB-500 for healing). Sequential use is preferable when you want to isolate effects or when peptides share receptor pathways. If running concurrent protocols, stagger start dates by 1-2 weeks to help attribute any initial effects to the correct compound.

Map out the entire research timeline on a calendar. Mark: compound start dates, on-cycle and off-cycle periods, measurement/assessment dates, compound expiration dates, and reorder points. Include buffer time for shipping and reconstitution. A well-planned calendar prevents gaps in supply and ensures washout periods are respected.

Maintain a running research log throughout all cycles. At the end of each on-cycle, document observed effects, any diminishing returns (potential desensitization), and notes for the next cycle. After the washout period, note which effects persisted and which faded. Use this data to refine cycle lengths and compound selections for subsequent research periods.